EED - Eye Exam for Patient with Diabetes

NCQA retired the Hybrid Method; this measure is now reported using the Administrative Method only.

Product Lines:
Advantage MD, EHP, Priority Partners, and USFHP.

Eligible Population:
Members 18-75 years old as of December 31 of the measurement year. This includes HealthChoice Performance Measure reporting for Priority Partners.

Definition:
Percentage of diabetic (types 1 and 2) members who had the following:

  • Eye Exam:
    • A retinal or dilated eye exam to detect retinopathy performed by an ophthalmologist or optometrist.
    • A diagnosis of retinopathy or an eye exam with an unknown retinal status requires an annual exam.
    • If negative for retinopathy, a bi-annual exam meets criteria.

Provider Specialty: Ophthalmologist or Optometrist.

Report Stratification by race and ethnicity.
Report Stratification by SES only for Advantage MD (Medicare product line).


Continuous Enrollment:

  • The measurement year.

Best Practice and Measure Tips

  • Provide member education on risks of Diabetic Eye Disease, and encourage scheduling annual exam.
  • Obtain eye exam reports. Notate eye care provider name and demographics in chart if report not available.
  • The dilated or retinal exam:  it is best practice to have a bilateral retinal exam unless there is history of a unilateral eye enucleation.
    • In some instances a unilateral retinal / dilated exam may be used if it meets guidelines for acceptable documentation. 
  • Documentation can be in the form of a note or letter prepared by an ophthalmologist, optometrist, PCP or other health care professional. Include: date of service, the test (indicate a dilated or retinal exam) or result, and the care provider’s credentials.
    • Documentation example: “Last diabetic retinal eye exam with John Smith, OD, was June 20XX with no retinopathy.”
  • Must indicate performed by Optometrist or Ophthalmologist.
  • A slit-lamp examination must have documentation of dilation or evidence that the retina was examined to be considered compliant.
  • Examination of macula, vessels and periphery without eye dilation meets criteria for a "retinal exam."
  • A chart or photograph with date of fundus photography or retinal imaging (Example: Computerized Ophthalmic Imaging such as Optical Coherence Tomography - OCT) and one of the following is acceptable:
    • Results read by a qualified reading center or by a system that provides an artificial intelligence (AI) interpretation.
    • Results reviewed by an eye care professional.
    • Results read by a qualified reading center operating under the direction of a medical director who is a retinal specialist.
  • Prior year exam results must indicate retinopathy was not present.
  • AI Reports:
    • Acceptable: “Negative for more than mild diabetic retinopathy”: This is only considered a negative result when it is a result of an exam read by AI (IDx-DR imaging system).
    • Documentation of Provider type for AI Reports:
      • If it is noted that an Optometrist or Ophthalmologist reviewed the AI results, then choose the appropriate provider type in the dropdown.
      • Some of the reports state they were read by AI and do not list a provider. If so, choose the provider dropdown option, “Results read by a system that provides an artificial intelligence (AI) interpretation.

Not Acceptable:

  • Routine fundoscopic exam without examination of macula, vessels and periphery.
  • Documentation of "diabetes without complications."
  • Exams performed by PCP or non-eye care professionals (optician)
  • Refractive only exams
  • Exams in which only the anterior (A) chamber of the eye is examined
  • Glaucoma pressure checks
  • Unilateral post-op eye exams which do not meet guidelines for acceptable documentation

Measure Exclusions

Required Exclusions:

  • Palliative Care
  • Members in hospice or using hospice services anytime during the measurement year.
  • Members who died any time during the measurement year.
  • Members 66 years of age and older as of December 31 of the measurement year (all product lines) with frailty and advanced illness.
  • Medicare members 66 years of age and older by the end of the measurement period who meet either of the following:
    • Enrolled in an Institutional SNP (I-SNP).
    • Living in Long Term Care.
  • Bilateral eye enucleation any time during the member’s history through December 31 of the measurement year

NOTE: Blindness is not an exclusion for a diabetic eye exam because it is difficult to distinguish between individuals who are legally blind but require a retinal exam and those who are completely blind and therefore do not require an exam.

Exclusion Codes:

  • Unilateral Eye Enucleation
    • CPT: 65091, 65093, 65101, 65103, 65105, 65110, 65112, 65114
  • Unilateral Eye Enucleation – Left
    • ICD10PCS: Diagnosis 08T1XZZ
  • Unilateral Eye Enucleation – Right
    • ICD10PCS: Diagnosis 08T0XZZ
  • Bilateral Modifier
    • CPT Modifier 50

Measure Codes

Codes that can only be bill by an Eye Care Professional (optometrist or ophthalmologist):

  • Retinal Eye Exams
    • CPT: 92235, 92230, 92250, 99245, 99243, 99244, 99242, 99205, 99203, 99204, 99215, 99213, 99214, 92018, 92019, 92004, 92002, 92014, 92012, 92202, 92201, 92134,
    • HCPCS: S3000, S0621, S0620
  • Diabetes Mellitus Without Complications
    • ICD-10-CM: E10.9, E11.9, E13.9

Codes that can be bill by ANY provider type:

  • Eye Exam With Evidence of Retinopathy
    • CPT-CAT-II: 2022F, 2024F, 2026F
  • Eye Exam Without Evidence of Retinopathy during current year or prior year
    • CPT-CAT-II: 2023F, 2025F, 2033F
  • Diabetic retinal screening negative in prior year:
    • CPT-CAT-II: 3072F
  • Automated Eye Exam:
    • CPT: 92229
  • Retinal Imaging
    • CPT: 92227, 92228
  • Any combination that indicates findings from a retinal exam for diabetic retinopathy performed in both the left and right eye:
    •  Left Eye:
      •  During the measurement year: Any level of retinopathy LOINC code 71490-7 with Diabetic Retinopathy Severity Level LOINC code LA18644-7, LA18645-4, LA18643-9, LA18648-8, LA18646-2.
      • In the year prior to the measurement year: No retinopathy LOINC code 71490-7 with LOINC code LA18643-9.
    • Right Eye:
      • During the measurement year: Any level of retinopathy LOINC code 71491-5 with Diabetic Retinopathy Severity LA18644-7, LA18645-4, LA18643-9, LA18648-8, LA18646-2.
      • In the year prior to the measurement year: No retinopathy LOINC code 71491-5 with LOINC code LA18643-9.

Medication List: Diabetes Medications

Description Prescription
Alpha-glucosidase inhibitors
  • Acarbose
  • Miglitol
Amylin analogs
  • Pramlintide
Antidiabetic combinations
  • Alogliptin-metformin 
  • Alogliptin-pioglitazone
  • Canagliflozin-metformin
  • Dapagliflozin-metformin
  • Dapagliflozin-saxagliptin
  • Empagliflozin-linagliptin
  • Empagliflozin-metformin
  • Empagliflozin-linagliptin-metformin
  • Ertugliflozin-metformin
  • Ertugliflozin-sitagliptin
  • Glimepiride-pioglitazone
  • Glipizide-metformin
  • Glyburide-metformin
  • Linagliptin-metformin 
  • Metformin-pioglitazone
  • Metformin-repaglinide
  • Metformin-rosiglitazone
  • Metformin-saxagliptin
  • Metformin-sitagliptin
Insulin
  • Insulin aspart 
  • Insulin aspart-insulin aspart protamine
  • Insulin degludec 
  • Insulin degludec-liraglutide
  • Insulin detemir
  • Insulin glargine
  • Insulin glargine-lixisenatide 
  • Insulin glulisine 
  • Insulin isophane human
  • Insulin isophane-insulin regular
  • Insulin lispro
  • Insulin lispro-insulin lispro protamine 
  • Insulin regular human
  • Insulin human inhaled
Meglitinides
  • Nateglinide    
  • Repaglinide
 Biguanides
  • Metformin
Glucagon-like peptide-1 (GLP1) agonists
  • Albiglutide 
  • Dulaglutide 
  • Exenatide    
  • Liraglutide
  • Lixisenatide 
  • Semaglutide
  • Tirzepatide
Sodium glucose cotransporter 2 (SGLT2) inhibitor
  • Canagliflozin  
  • Dapagliflozin
  • Empagliflozin
  • Ertugliflozin
Sulfonylureas
  • Chlorpropamide
  • Glimepiride  
  •  Glipizide
  • Glyburide  
  • Tolazamide 
  • Tolbutamide
Thiazolidinediones
  • Pioglitazone    
  • Rosiglitazone
Dipeptidyl peptidase-4 (DDP-4) inhibitors
  • Alogliptin   
  • Linagliptin    
  • Saxagliptin
  • Sitagliptin